Enhancing the Outcome of Crystallographic Fragment Screening by Choosing the Optimal Protein Crystal Form
Small Science · 2026-03 · 6 (3)
DOI: 10.1002/smsc.202500484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Science, online erschienen am 04.03.2026. Verfasst von Tatjana Barthel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Macromolecular Crystallography Helmholtz-Zentrum Berlin Berlin Germany. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020, European Commission, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Improving health and quality of life in our society is a key focus of drug development. Methods for drug discovery are being optimized in multiple ways to reduce costs and timelines. Crystallographic fragment screening (CFS) is increasingly being employed as an early screening method in drug discovery projects. Here, we demonstrate that selecting the optimal protein crystal form can significantly impact hit rates. Two CFS campaigns are carried out against the two crystal forms of the SARS‐CoV‐2 main protease, using the same fragment library and an almost identical experimental setup. Although both crystal forms exhibit similar diffraction properties, the observed hit rates in the two campaigns differ significantly. A hit rate of 3% is determined for the monoclinic crystals, while a hit rate of 16% is observed for the orthorhombic crystals. These findings are consistent with the more open molecular packing in the orthorhombic crystals, where the solvent channels leading to the active sites are approximately twice the size of those in the monoclinic crystal form. Our results highlight the critical importance of the crystal form in a crystallographic screening, identifying it as one of the most important parameters to optimize when preparing a CFS campaign.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Macromolecular Crystallography Helmholtz-Zentrum Berlin Berlin Germany.
- Proteros biostructures GmbH München Planegg-Martinsried Germany.
- Biomedical Research with X-rays (FS-BMX) Deutsches Elektronen-Synchrotron DESY Hamburg Germany.
- Institute of Molecular Medicine University of Lübeck Lübeck Schleswig-Holstein Germany.
- Institute of Biology Humboldt-Universität zu Berlin Berlin Germany.
ORCID-Profile: Tatjana Barthel, Manfred S Weiss
Förderung
- Horizon 2020
- European Commission
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Barthel, T., Wollenhaupt, J., Benz, L. S., Reinke, P., Zhang, L., Oelker, M., Lennartz, F., Taberman, H., Mueller, U., Meents, A., Hilgenfeld, R., & Weiss, M. S. (2026). Enhancing the Outcome of Crystallographic Fragment Screening by Choosing the Optimal Protein Crystal Form. Small Science, 6(3). https://doi.org/10.1002/smsc.202500484
Vancouver
Barthel T, Wollenhaupt J, Benz LS, Reinke P, Zhang L, Oelker M, et al. Enhancing the Outcome of Crystallographic Fragment Screening by Choosing the Optimal Protein Crystal Form. Small Science. 2026;6(3). doi:10.1002/smsc.202500484
BibTeX
@article{Barthel2026,
author = {Barthel, Tatjana and Wollenhaupt, Jan and Benz, Laila S and Reinke, Patrick and Zhang, Linlin and Oelker, Melanie and Lennartz, Frank and Taberman, Helena and Mueller, Uwe and Meents, Alke and Hilgenfeld, Rolf and Weiss, Manfred S},
title = {Enhancing the Outcome of Crystallographic Fragment Screening by Choosing the Optimal Protein Crystal Form},
journal = {Small Science},
year = {2026},
volume = {6},
number = {3},
doi = {10.1002/smsc.202500484}
}
EUVIMED